The global fondaparinux market size is estimated to register a significant CAGR during the forecast period, 2021-2028. The growth of the market is due to the increasing population base that is health-conscious along with the availability of alternatives for generics. It is high in demand as they are more efficient as well as have low chances of severe bleeding and mortality post administration as compare to low-molecular-weight heparin.
Fondaparinux, also known as Arixtra, is a synthetic anticoagulant that is similar to low-molecular-weight heparin used to prevent and treat deep vein thrombosis and pulmonary embolism in patients who have had orthopedic surgery. The U.S. Food and Drug Administration (FDA) approved Arixtra which is the generic version of fondaparinux in order to treat the above-mentioned disorders. Arixtra was established as a safe alternative for patients with thrombocytopenia by the Piedmont Hospital of Atlanta. The long-term use of fondaparinux was also established by the researchers for the treatment of cancer in November 2014. Anticoagulants are given to patients who fall under the category of geriatric population and suffered from heart attack and angina.
The COVID-19 pandemic had caused a positive impact on the fondaparinux market as the mortality rate in COVID-19 patients decreased due to the usage of heparin. Several initial studies had shown positive results as it impacts on the mortality rate reduction of COVID-19 patients who were hospitalized. However, later it was suggested to use only low-molecular-weight heparin for the treatment of patients with venous thromboembolism having mild COVID-19 infection. It also can be used to some extent due to lack of an antidote. Different studies have different opinions regarding the usage of fondaparinux for patients being infected with COVID-19, which is anticipated to have an impact on the market.
Market Trends, Drivers, Restraints, and Opportunities
- Wide prevalence of thrombocytosis along with the rising demand for effective therapeutics are expected to fuel the market growth.
- Wide prevalence of several diseases among the rapidly growing geriatric population is anticipated to propel the market growth during the forecast period.
- Rising cases of chronic disorders such as cardiovascular diseases and diabetes is estimated to drive the market expansion in the coming years.
- Absence or insufficient awareness about venous thromboembolism conditions is a key challenge that can restrain the market growth.
- Ongoing research & development activities in order to find broader applications of fondaparinux are projected to create lucrative opportunities for the market growth.
Scope of the Report
The report on the global fondaparinux market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Fondaparinux Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Product Types (Generic Fondaparinux and Branded Fondaparinux) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Alchemia SA; Mylan N.V.; GSK; and Dr. Reddy’s Laboratories, Inc. |
Market Segment Insights
Generic Fondaparinux is expected to expand at a lucrative CAGR
On the basis of product types, the global fondaparinux market is bifurcated into generic fondaparinux and branded fondaparinux. The generic fondaparinux is expected to expand at a lucrative CAGR during the forecast period due to advancements in its manufacturing facilities. The complexity of manufacturing process of the products often leads to its high cost and results in limited consumption. However, the reduction of difficulties to a great extent in this process is anticipated to drive the market segment growth. Several initiatives taken by various government and the rapid development of healthcare facilities in order to promote the usage of generic drugs are also expected to help in the market segment expansion.
North America is anticipated to dominate the market
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market during the projected period attributed to rising incidence of disorders such as neurological, hematological, and cardiovascular. Moreover, increasing incidence of blood tumors and development & launch of various generic drugs in the region play important roles for the regional market development. Meanwhile, Asia Pacific is emerging to be the power hub for sourcing & manufacturing various formulations of drugs and is estimated to constitute a key market share in the coming years due to the presence of a targeted population base and increasing clinical needs for various unmet patients in the region.
Segments
Segments Covered in the Report
The global fondaparinux market has been segmented on the basis of
Product Types
- Generic Fondaparinux
- Branded Fondaparinux
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Alchemia SA
- Mylan N.V.
- GSK
- Dr. Reddy’s Laboratories, Inc.
Competitive Landscape
Key players competing in the global fondaparinux market are Alchemia SA; Mylan N.V.; GSK; and Dr. Reddy’s Laboratories, Inc. Many of these players have adopted business strategies such as launch of new products, advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their expansion, their consumer base, and market position globally.
For example, Mylan N.V. acquired the U.S. IP rights and marketing from Aspen Global, Inc. in September 2014 for the Arixtra injection and its generic form. In another event, Alchemia Ltd. entered into a partnership with Dr. Reddy’s Laboratories Ltd. as a strategic alliance and together launched a drug in 2011 in the U.S.
Request For Customization
Enquiry Before Buying
Speak With Analyst
